TG Therapeutics (NASDAQ:TGTX) Price Target Raised to $55.00 at B. Riley

TG Therapeutics (NASDAQ:TGTX) had its price target increased by B. Riley from $53.00 to $55.00 in a research note released on Wednesday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Separately, The Goldman Sachs Group raised shares of TG Therapeutics to a “hold” rating and set a $37.00 price objective on the stock in a research note on Thursday, July 10th. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, TG Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $48.00.

TG Therapeutics Stock Up 0.2%

TGTX stock opened at $32.04 on Wednesday. The company has a current ratio of 3.86, a quick ratio of 2.96 and a debt-to-equity ratio of 0.89. TG Therapeutics has a twelve month low of $21.16 and a twelve month high of $46.48. The company’s 50 day moving average is $32.11 and its two-hundred day moving average is $35.68. The stock has a market cap of $5.08 billion, a P/E ratio of 86.59 and a beta of 1.88.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.15). The company had revenue of $141.15 million for the quarter, compared to analyst estimates of $147.76 million. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The firm’s revenue for the quarter was up 92.1% compared to the same quarter last year. During the same period in the previous year, the business posted $0.04 EPS. TG Therapeutics has set its FY 2025 guidance at EPS. Research analysts expect that TG Therapeutics will post 0.08 earnings per share for the current fiscal year.

Insider Activity at TG Therapeutics

In related news, Director Sagar Lonial sold 20,852 shares of the business’s stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $32.24, for a total value of $672,268.48. Following the sale, the director directly owned 94,061 shares in the company, valued at $3,032,526.64. The trade was a 18.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.64% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Thrivent Financial for Lutherans increased its stake in shares of TG Therapeutics by 1.7% during the 2nd quarter. Thrivent Financial for Lutherans now owns 99,715 shares of the biopharmaceutical company’s stock valued at $3,589,000 after acquiring an additional 1,677 shares during the last quarter. Marex Group plc acquired a new position in shares of TG Therapeutics during the 2nd quarter valued at about $10,017,000. Advisory Services Network LLC increased its stake in shares of TG Therapeutics by 66.3% during the 2nd quarter. Advisory Services Network LLC now owns 20,205 shares of the biopharmaceutical company’s stock valued at $717,000 after acquiring an additional 8,054 shares during the last quarter. Hohimer Wealth Management LLC acquired a new position in shares of TG Therapeutics during the 2nd quarter valued at about $308,000. Finally, Geneos Wealth Management Inc. increased its stake in shares of TG Therapeutics by 200.0% during the 2nd quarter. Geneos Wealth Management Inc. now owns 2,169 shares of the biopharmaceutical company’s stock valued at $78,000 after acquiring an additional 1,446 shares during the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.